{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:04:42Z","timestamp":1787313882569,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":976,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1124\/dmd.121.000733","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T18:50:10Z","timestamp":1644605410000},"page":"613-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and\/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model"],"prefix":"10.1016","volume":"50","author":[{"given":"Jinfu","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur K.","family":"Ladumor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashvant D.","family":"Unadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000733_bib1","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fphar.2019.01672","article-title":"Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in paediatrics","volume":"10","author":"Adiwidjaja","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1124\/dmd.121.000733_bib3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/psp4.12674","article-title":"Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome","volume":"10","author":"Anoshchenko","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1124\/dmd.120.000067","article-title":"Gestational age-dependent abundance of human placental transporters as determined by quantitative targeted proteomics","volume":"48","author":"Anoshchenko","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/dmd.121.000538","article-title":"Successful prediction of human fetal exposure to P-glycoprotein substrate drugs using the proteomics-informed relative expression factor approach and PBPK modeling and simulation","volume":"49","author":"Anoshchenko","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105068","article-title":"Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies","volume":"140","author":"Atoyebi","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.121.000733_bib7","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.121.000733_bib8","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1124\/dmd.121.000733_bib9","doi-asserted-by":"crossref","first-page":"32939","DOI":"10.1021\/acsomega.0c03930","article-title":"Contribution of uptake and efflux transporters to oral pharmacokinetics of furosemide","volume":"5","author":"Chapa","year":"2020","journal-title":"ACS Omega"},{"key":"10.1124\/dmd.121.000733_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/10428194.2017.1347929","article-title":"Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment","volume":"59","author":"Chelysheva","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1124\/dmd.121.000733_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0b013e31823ff052","article-title":"Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum","volume":"59","author":"Cressey","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.121.000733_bib12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0091270006292164","article-title":"Pharmacokinetics of nelfinavir in subjects with hepatic impairment","volume":"46","author":"Damle","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40262-015-0360-5","article-title":"Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-na\u00efve HIV-infected patients at 96 weeks: results of the ENCORE1 study","volume":"55","author":"Dickinson","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000733_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/dmd.112.047118","article-title":"Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy","volume":"41","author":"Dickmann","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s11095-006-0279-5","article-title":"Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier","volume":"23","author":"Dirson","year":"2006","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.121.000733_bib16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","article-title":"Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions","volume":"35","author":"Dixit","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","article-title":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects","volume":"54","author":"Dutreix","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1310\/hct1301-46","article-title":"Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum","volume":"13","author":"Fang","year":"2012","journal-title":"HIV Clin Trials"},{"key":"10.1124\/dmd.121.000733_bib19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.104.065342","article-title":"HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"310","author":"Gupta","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000733_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/AOG.0000000000002579","article-title":"Prescription and other medication use in pregnancy","volume":"131","author":"Haas","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1124\/dmd.121.000733_bib22","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesilate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000733_bib23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2007.02885.x","article-title":"Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples","volume":"64","author":"Hirt","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib24","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.121.000733_bib25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/jac\/dkp335","article-title":"Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes","volume":"64","author":"Janneh","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.121.000733_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5414\/CPP43154","article-title":"Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects","volume":"43","author":"Kaeser","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000733_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215906","article-title":"Empirical models for anatomical and physiological changes in a human mother and fetus during pregnancy and gestation","volume":"14","author":"Kapraun","year":"2019","journal-title":"PLoS One"},{"key":"10.1124\/dmd.121.000733_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/dmd.112.050161","article-title":"A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women","volume":"41","author":"Ke","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib29","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1038\/psp.2012.2","article-title":"A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction","volume":"1","author":"Ke","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bcp.12207","article-title":"Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19","volume":"77","author":"Ke","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":"The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors","volume":"101","author":"Kim","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.121.000733_bib32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3851\/IMP3283","article-title":"Efavirenz pharmacokinetics during pregnancy and infant washout","volume":"24","author":"Kreitchmann","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.121.000733_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/dmd.120.000204","article-title":"Prediction of transporter-mediated rosuvastatin hepatic uptake clearance and drug Interaction in humans using proteomics-informed REF approach","volume":"49","author":"Kumar","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1067\/mcp.2002.126178","article-title":"Low-dose ritonavir moderately enhances nelfinavir exposure","volume":"72","author":"Kurowski","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000733_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1124\/dmd.119.086462","article-title":"Ontogeny of hepatic sulfotransferases and prediction of age-dependent fractional contribution of sulfation in acetaminophen metabolism","volume":"47","author":"Ladumor","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib37","doi-asserted-by":"crossref","first-page":"9709","DOI":"10.1038\/s41598-019-45778-9","article-title":"A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation","volume":"9","author":"Ladumor","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.121.000733_bib38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciy161","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz 400 mg once daily during pregnancy and post-partum","volume":"67","author":"Lamorde","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.121.000733_bib39","first-page":"609","article-title":"Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate","volume":"26","author":"Lillibridge","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/jps.2600840911","article-title":"Preformulation studies of a novel HIV protease inhibitor, AG1343","volume":"84","author":"Longer","year":"1995","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000733_bib41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","article-title":"Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","volume":"303","author":"Mahar Doan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000733_bib42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/46.5.657","article-title":"Prevention of perinatal HIV transmission during pregnancy","volume":"46","author":"McGowan","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.121.000733_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.121.000733_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1468-1293.2006.00356.x","article-title":"Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions","volume":"7","author":"Motoya","year":"2006","journal-title":"HIV Med"},{"key":"10.1124\/dmd.121.000733_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","article-title":"The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib","volume":"27","author":"Oostendorp","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.121.000733_bib46","first-page":"843","article-title":"Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers","volume":"71","author":"Ostrowicz","year":"2014","journal-title":"Acta Pol Pharm"},{"key":"10.1124\/dmd.121.000733_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.118.085548","article-title":"Hepatic enzymes relevant to the disposition of (-)-\u03949-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","article-title":"Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion","volume":"44","author":"Peng","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib49","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bcp.2011.07.081","article-title":"Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2\/BCRP in the gastrointestinal tract of the rat","volume":"82","author":"Peroni","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib50","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.2165\/00003495-200565150-00015","article-title":"Nelfinavir: a review of its use in the management of HIV infection","volume":"65","author":"Perry","year":"2005","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000733_bib51","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods","volume":"98","author":"Poulin","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000733_bib52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1468-1293.2008.00640.x","article-title":"Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum","volume":"9","author":"Read","year":"2008","journal-title":"HIV Med"},{"key":"10.1124\/dmd.121.000733_bib53","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/jps.20344","article-title":"The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice","volume":"94","author":"Salama","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000733_bib54","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0091270005280051","article-title":"The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers","volume":"45","author":"Sarapa","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejpb.2011.04.005","article-title":"Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir","volume":"79","author":"Shono","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/dmd.121.000733_bib56","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/clpt.2012.61","article-title":"Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model","volume":"92","author":"Siccardi","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000733_bib57","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s11095-006-0162-4","article-title":"Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test","volume":"23","author":"Takano","year":"2006","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.121.000733_bib58","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/978-1-0716-1554-6_18","article-title":"Ontogeny of drug-metabolizing enzymes","volume":"2342","author":"Thakur","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.121.000733_bib59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/A:1023433502647","article-title":"Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate","volume":"20","author":"Tolle-Sander","year":"2003","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.121.000733_bib60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1389200043489171","article-title":"Placental drug transporters","volume":"5","author":"Unadkat","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000733_bib61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clpt.2004.08.011","article-title":"The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum","volume":"76","author":"van Heeswijk","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000733_bib62","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2125.1999.00071.x","article-title":"Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients","volume":"48","author":"Villani","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000733_bib63","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14656566.8.6.851","article-title":"Efavirenz: a review","volume":"8","author":"Vrouenraets","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/dmd.121.000733_bib64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/clpt.2011.102","article-title":"Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia","volume":"90","author":"Yamakawa","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000733_bib65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0928-0987(00)00076-2","article-title":"Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells","volume":"10","author":"Yamashita","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.121.000733_bib66","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/AAC.45.4.1086-1093.2001","article-title":"Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities","volume":"45","author":"Zhang","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.121.000733_bib67","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.114.062984","article-title":"Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes","volume":"43","author":"Zhang","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib68","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/dmd.117.075192","article-title":"Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/dmd.116.073957","article-title":"Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000733_bib70","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1124\/dmd.108.024489","article-title":"The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice","volume":"37","author":"Zhou","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:53:12Z","timestamp":1739937192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624007906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0090955624007906"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000733","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and\/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s)","name":"copyright","label":"Copyright"}]}}